CA3234699A1 - Methods for treating cancers and tumors - Google Patents
Methods for treating cancers and tumors Download PDFInfo
- Publication number
- CA3234699A1 CA3234699A1 CA3234699A CA3234699A CA3234699A1 CA 3234699 A1 CA3234699 A1 CA 3234699A1 CA 3234699 A CA3234699 A CA 3234699A CA 3234699 A CA3234699 A CA 3234699A CA 3234699 A1 CA3234699 A1 CA 3234699A1
- Authority
- CA
- Canada
- Prior art keywords
- substituted
- cancer
- compound
- formula
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163253332P | 2021-10-07 | 2021-10-07 | |
| US63/253,332 | 2021-10-07 | ||
| PCT/US2022/077702 WO2023060200A1 (en) | 2021-10-07 | 2022-10-06 | Methods for treating cancers and tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3234699A1 true CA3234699A1 (en) | 2023-04-13 |
Family
ID=85804784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3234699A Pending CA3234699A1 (en) | 2021-10-07 | 2022-10-06 | Methods for treating cancers and tumors |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240408082A1 (https=) |
| EP (1) | EP4412613A4 (https=) |
| JP (1) | JP2024538730A (https=) |
| CN (1) | CN118369101A (https=) |
| CA (1) | CA3234699A1 (https=) |
| WO (1) | WO2023060200A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7025416B2 (ja) | 2016-06-06 | 2022-02-24 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | 好中球減少症を低減させるための組成物および方法 |
| BR112019015974A2 (pt) | 2017-02-01 | 2020-03-31 | Beyondspring Pharmaceuticals, Inc. | Método para reduzir neutropenia |
| CA3215047A1 (en) | 2021-04-09 | 2022-10-13 | Lan Huang | Therapeutic compositions and methods for treating tumors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005212399B2 (en) * | 2004-02-04 | 2011-09-22 | Nereus Pharmaceuticals, Inc. | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof |
| AU2016229294B2 (en) * | 2015-03-06 | 2021-11-04 | Beyondspring Pharmaceuticals, Inc. | Method of treating cancer associated with a RAS mutation |
| MX2021001762A (es) * | 2018-08-16 | 2021-04-19 | Beyondspring Pharmaceuticals Inc | Metodo y composicion para estimular la respuesta inmunitaria. |
| JP2022513038A (ja) * | 2018-11-14 | 2022-02-07 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | チューブリン結合薬を使用する癌の治療方法 |
-
2022
- 2022-10-06 WO PCT/US2022/077702 patent/WO2023060200A1/en not_active Ceased
- 2022-10-06 US US18/698,677 patent/US20240408082A1/en active Pending
- 2022-10-06 EP EP22879497.0A patent/EP4412613A4/en active Pending
- 2022-10-06 JP JP2024521109A patent/JP2024538730A/ja active Pending
- 2022-10-06 CA CA3234699A patent/CA3234699A1/en active Pending
- 2022-10-06 CN CN202280081569.8A patent/CN118369101A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023060200A1 (en) | 2023-04-13 |
| EP4412613A4 (en) | 2025-10-22 |
| US20240408082A1 (en) | 2024-12-12 |
| CN118369101A (zh) | 2024-07-19 |
| JP2024538730A (ja) | 2024-10-23 |
| EP4412613A1 (en) | 2024-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240408082A1 (en) | Methods for treating cancers and tumors | |
| US11918574B2 (en) | Method of treating cancer associated with a RAS mutation | |
| AU2002210993B2 (en) | Medicinal compositions for concominant use as anticancer agents | |
| US20110160295A1 (en) | Antitumor agent | |
| JP6754071B2 (ja) | メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用 | |
| US6921772B2 (en) | Methods and compositions for the treatment of chronic lymphocytic leukemia | |
| US8372830B2 (en) | Methods for using vasopressin antagonists with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival | |
| US12257237B2 (en) | Tinostamustine for use in treating sarcoma | |
| US20190262319A1 (en) | Novel methods for treating cancer | |
| CN104918630A (zh) | 抗药性癌细胞的抑制 | |
| US20190231793A1 (en) | Use of harringtonines in the treatment of breast cancer, in particular triple-negative breast cancer | |
| HK40109587A (zh) | 治疗癌症和肿瘤的方法 | |
| US20240051969A1 (en) | Ror-gamma inhibitors for the treatment of ror-gamma-dependent cancer | |
| AU2008356312B2 (en) | Antitumor agent, kit, and method for treating cancer | |
| NZ551637A (en) | Antitumor effect fortifier, antitumor agent and method of therapy for cancer | |
| JP2026509292A (ja) | 腫瘍学的併用療法及びその使用方法 | |
| JP2022547702A (ja) | 胆管癌の処置のためのパノビノスタットを含む併用療法 | |
| KR20260019493A (ko) | 종양 병용 요법 및 사용 방법 | |
| WO2018181820A1 (ja) | 複素環化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - SMALL Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240906 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240906 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240906 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - SMALL Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250908 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250908 |